The estimated Net Worth of David F Novack is at least $5.16 millió dollars as of 10 February 2024. Mr Novack owns over 8,833 units of Dynavax Technologies stock worth over $262,211 and over the last 12 years he sold DVAX stock worth over $4,094,795. In addition, he makes $799,198 as Pres & COO at Dynavax Technologies.
Mr has made over 30 trades of the Dynavax Technologies stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 8,833 units of DVAX stock worth $96,368 on 10 February 2024.
The largest trade he's ever made was exercising 52,500 units of Dynavax Technologies stock on 10 February 2022 worth over $572,775. On average, Mr trades about 12,776 units every 49 days since 2013. As of 10 February 2024 he still owns at least 24,034 units of Dynavax Technologies stock.
You can see the complete history of Mr Novack stock trades at the bottom of the page.
David F. Novack is the Pres & COO at Dynavax Technologies.
As the Pres & COO of Dynavax Technologies, the total compensation of Mr Novack at Dynavax Technologies is $799,198. There are 1 executives at Dynavax Technologies getting paid more, with Ryan Spencer having the highest compensation of $859,990.
Mr Novack is 59, he's been the Pres & COO of Dynavax Technologies since . There are 2 older and 3 younger executives at Dynavax Technologies. The oldest executive at Dynavax Technologies Corp. is Michael S. Ostrach, 69, who is the Advisor.
David's mailing address filed with the SEC is C/O DYNAVAX TECHNOLOGIES, 2100 POWELL STREET, SUITE 720, EMERYVILLE, CA, 94608.
Over the last 21 years, insiders at Dynavax Technologies have traded over $196,839,440 worth of Dynavax Technologies stock and bought 2,463,112 units worth $11,318,051 . The most active insiders traders include Andrew A. F. Hack, Partners L P/Ilbiotechnolog... és James Edeerfield Capital Lp.... On average, Dynavax Technologies executives and independent directors trade stock every 43 days with the average trade being worth of $1,533,390. The most recent stock trade was executed by Francis Cano on 31 May 2024, trading 3,615 units of DVAX stock currently worth $43,127.
dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.
Dynavax Technologies executives and other stock owners filed with the SEC include: